30/81
1.9 / 5 stars
All 81 Win/Lose results and 39 gray no-data contests shown below
NKTR Roast Me summary
NEKTAR THERAPEUTICS (NKTR). Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth No data.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth No data.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth No data.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth No data.
Trailing 1 year (4 quarters): 2 wins, 6 losses, 4 no dataLast fetched: 24 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/2 |
LoseNKTR / S&P -2.97% / 15.20% |
LoseNKTR / S&P -27.15% / 15.00% |
No dataNKTR / S&P / 50.40% |
| 2026-Q11/2 |
WinNKTR / S&P 70.18% / -4.33% |
LoseNKTR / S&P -36.24% / 11.30% |
No dataNKTR / S&P / 27.70% |
| 2025-Q40/2 |
LoseNKTR / S&P -25.69% / 2.65% |
LoseNKTR / S&P -43.89% / 9.00% |
No dataNKTR / S&P / 13.40% |
| 2025-Q31/2 |
WinNKTR / S&P 120.20% / 8.12% |
LoseNKTR / S&P -32.79% / 4.61% |
No dataNKTR / S&P / 13.45% |
| 2025-Q21/2 |
WinNKTR / S&P 153.33% / 10.94% |
LoseNKTR / S&P -19.56% / 4.83% |
No dataNKTR / S&P / 10.63% |
| 2025-Q10/2 |
LoseNKTR / S&P -26.88% / -4.27% |
LoseNKTR / S&P -3.24% / 4.98% |
No dataNKTR / S&P / 10.57% |
| 2024-Q41/2 |
LoseNKTR / S&P -28.46% / 2.41% |
WinNKTR / S&P 9.22% / 5.25% |
No dataNKTR / S&P / 6.15% |
| 2024-Q30/2 |
LoseNKTR / S&P 4.84% / 5.89% |
LoseNKTR / S&P 5.53% / 5.89% |
No dataNKTR / S&P / 6.11% |
| 2024-Q22/2 |
WinNKTR / S&P 33.33% / 4.28% |
WinNKTR / S&P 6.17% / 5.38% |
No dataNKTR / S&P / 5.12% |
| 2024-Q11/2 |
WinNKTR / S&P 66.07% / 10.56% |
LoseNKTR / S&P 1.51% / 5.71% |
No dataNKTR / S&P / 5.59% |
| 2023-Q40/2 |
LoseNKTR / S&P -6.67% / 11.69% |
LoseNKTR / S&P -2.10% / 6.81% |
No dataNKTR / S&P / 7.78% |
| 2023-Q31/2 |
WinNKTR / S&P 3.45% / -3.27% |
LoseNKTR / S&P -7.13% / 7.52% |
No dataNKTR / S&P / -5.03% |
| 2023-Q20/2 |
LoseNKTR / S&P -17.14% / 8.74% |
LoseNKTR / S&P -8.92% / 9.50% |
No dataNKTR / S&P / -8.57% |
| 2023-Q10/2 |
LoseNKTR / S&P -69.03% / 7.50% |
LoseNKTR / S&P -13.83% / 10.77% |
No dataNKTR / S&P / -15.69% |
| 2022-Q40/2 |
LoseNKTR / S&P -29.37% / 7.56% |
LoseNKTR / S&P -9.67% / 11.88% |
No dataNKTR / S&P / -17.99% |
| 2022-Q30/2 |
LoseNKTR / S&P -15.79% / -4.88% |
LoseNKTR / S&P -5.30% / 13.47% |
No dataNKTR / S&P / -1.41% |
| 2022-Q20/2 |
LoseNKTR / S&P -29.50% / -16.10% |
LoseNKTR / S&P -8.66% / 13.71% |
No dataNKTR / S&P / 11.04% |
| 2022-Q10/2 |
LoseNKTR / S&P -60.10% / -4.60% |
LoseNKTR / S&P -18.18% / 15.97% |
No dataNKTR / S&P / 42.23% |
| 2021-Q40/2 |
LoseNKTR / S&P -24.78% / 11.03% |
LoseNKTR / S&P -33.36% / 15.00% |
No dataNKTR / S&P / 96.40% |
| 2021-Q31/2 |
WinNKTR / S&P 4.66% / 0.58% |
LoseNKTR / S&P -38.55% / 10.77% |
No dataNKTR / S&P / 69.42% |
| 2021-Q20/2 |
LoseNKTR / S&P -14.20% / 8.55% |
LoseNKTR / S&P -35.09% / 6.58% |
No dataNKTR / S&P / 51.81% |
| 2021-Q11/2 |
WinNKTR / S&P 17.65% / 6.17% |
LoseNKTR / S&P -8.02% / -1.06% |
No dataNKTR / S&P / 7.39% |
| 2020-Q41/2 |
LoseNKTR / S&P 2.47% / 12.15% |
WinNKTR / S&P 33.41% / -3.72% |
No dataNKTR / S&P / -33.42% |
| 2020-Q31/2 |
LoseNKTR / S&P -28.37% / 8.93% |
WinNKTR / S&P 35.44% / -2.04% |
No dataNKTR / S&P / -27.10% |
| 2020-Q22/2 |
WinNKTR / S&P 29.75% / 20.54% |
WinNKTR / S&P 36.41% / -0.46% |
No dataNKTR / S&P / -27.11% |
| 2020-Q11/2 |
WinNKTR / S&P -17.32% / -19.60% |
LoseNKTR / S&P -88.43% / 3.47% |
No dataNKTR / S&P / -14.75% |
| 2019-Q41/3 |
WinNKTR / S&P 18.50% / 9.07% |
LoseNKTR / S&P -90.40% / 5.36% |
LoseNKTR / S&P -166.67% / 2.99% |
| 2019-Q30/2 |
LoseNKTR / S&P -48.79% / 1.70% |
LoseNKTR / S&P -90.35% / 5.02% |
No dataNKTR / S&P / 0.21% |
| 2019-Q21/2 |
WinNKTR / S&P 5.89% / 4.30% |
LoseNKTR / S&P -91.33% / 6.64% |
No dataNKTR / S&P / 8.65% |
| 2019-Q11/2 |
LoseNKTR / S&P 2.22% / 13.65% |
WinNKTR / S&P 268.70% / 8.12% |
No dataNKTR / S&P / 14.29% |
| 2018-Q41/2 |
LoseNKTR / S&P -46.08% / -13.52% |
WinNKTR / S&P 287.81% / 9.05% |
No dataNKTR / S&P / 18.23% |
| 2018-Q32/2 |
WinNKTR / S&P 24.84% / 7.71% |
WinNKTR / S&P 400.19% / 10.21% |
No dataNKTR / S&P / 19.06% |
| 2018-Q21/2 |
LoseNKTR / S&P -54.05% / 3.43% |
WinNKTR / S&P 932.36% / 9.03% |
No dataNKTR / S&P / 14.46% |
| 2018-Q12/2 |
WinNKTR / S&P 77.93% / -0.76% |
WinNKTR / S&P 144.51% / 7.68% |
No dataNKTR / S&P / 12.46% |
| 2017-Q42/2 |
WinNKTR / S&P 148.83% / 6.64% |
WinNKTR / S&P 86.00% / 7.03% |
No dataNKTR / S&P / 13.82% |
| 2017-Q32/2 |
WinNKTR / S&P 22.76% / 4.48% |
WinNKTR / S&P 49.20% / 5.68% |
No dataNKTR / S&P / 17.57% |
| 2017-Q20/2 |
LoseNKTR / S&P -16.70% / 3.09% |
LoseNKTR / S&P -30.30% / 4.83% |
No dataNKTR / S&P / 17.74% |
| 2017-Q11/2 |
WinNKTR / S&P 91.28% / 6.07% |
LoseNKTR / S&P -27.41% / 3.67% |
No dataNKTR / S&P / 13.32% |
| 2016-Q40/2 |
LoseNKTR / S&P -28.58% / 3.82% |
LoseNKTR / S&P -28.32% / 2.09% |
No dataNKTR / S&P / 7.05% |
| 2016-Q31/2 |
WinNKTR / S&P 20.73% / 3.85% |
LoseNKTR / S&P -20.67% / 0.20% |
No dataNKTR / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | NKTR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 143.10% | 20.78% |
| Annualized return | 143.10% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | NKTR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -69.29% | 83.14% |
| Annualized return | -21.03% | 12.86% |
10Y · 2016-09-01 to 2026-08-28
| Metric | NKTR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -73.28% | 319.30% |
| Annualized return | -12.36% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-24.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |